Healthcare Industry News:  Calypso Medical Technologies 

Devices Oncology

 News Release - November 6, 2006

Continuous, Real-Time Tumor Localization Monitoring System Launches at ASTRO

Calypso(R) Medical Technologies, Inc. Investigators Present Real-Time Prostate Motion Data at ASTRO's 48th Annual Meeting

PHILADELPHIA, Nov. 6 (HSMN NewsFeed) -- Reports of scientific investigations of the Calypso 4DŽ Localization System will be presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) 48th Annual Scientific Meeting. These abstracts discuss investigations supporting continuous, real-time target localization and tumor tracking in a variety of potential clinical applications.

CalypsoŽ Medical Technologies, Inc. this year received FDA 510(k) clearance for the system, which utilizes proprietary electromagnetic technology in conjunction with implanted BeaconŽ Electromagnetic Transponders, in the prostate. The product platform is designed to provide objective, accurate and continuous tumor location information during external beam radiation therapy without adding ionizing radiation. Offering the first and only means to continuously and objectively monitor prostate organ motion during radiation therapy, Calypso Medical is launching the technology at the ASTRO meeting.

The CalypsoŽ System was evaluated in patients undergoing prostate radiation treatment between 2003 and 2006 at leading cancer centers. In these studies, investigators documented clinically-relevant prostate motion was present in the majority of patients. The prostate motion was unpredictable and variable patient to patient and throughout the treatment course. Utilizing the guidance from the CalypsoŽ System, clinicians were able to respond to out-of-threshold conditions in real-time, to manage organ motion with individual institutional protocols.

Calypso Medical's technology will be highlighted in ten scientific abstracts presented at the ASTRO 48th Annual Meeting in Philadelphia at the Pennsylvania Convention Center, November 5 - 9, 2006, and published simultaneously in the International Journal of Radiation Oncology Biology * Physics. The Calypso System will be available for demonstration viewing at Calypso Medical's booth, No. 2151. Presentations include:

In-Vivo Comparison of an Electromagnetic System to Standard kV X-Rays for Treatment Setup During External Beam Radiotherapy of Patients with Prostate Cancer

Presented by S. Jani, PhD, Sharp Memorial Hospital, San Diego, CA

November 5, 2:55pm, Convention Center Room 204, Scientific Session * Treatment Planning and Delivery: Prostate * Oral Presentation # 139

Characterization of External Breathing Surrogate using Implanted Electromagnetic Transponders in Canine Lungs

Presented by K M Lechleiter, B.S., Washington University Medical School, St. Louis, MO

November 7, 12:00 pm, Convention Center Room 204, Scientific Session * 4D and Deformation * Oral Presentation #97

Position Correction Guidance Utilizing Real-Time Tracking with the CalypsoŽ System for External Radiation Therapy Delivery in Patients with Localized Prostate Cancer

Presented by T. Willoughby, M.S., M. D. Anderson Cancer Center Orlando, FL

November 6, Convention Center Room 108, Poster Discussion 2 * Physics #1017

Characterization of Real Time Motion of the Prostate Gland in Patients Receiving External Radiotherapy for Localization Prostate Cancer: Tracking During 1157 Fractions with the CalypsoŽ System

Presented by P.A. Kupelian, M.D., M. D. Anderson Cancer Center Orlando, FL

November 9, 1:00 pm Convention Center Room 108, Poster Discussion 9 * Genitourinary Cancer #1136

Tolerance, Stability and Reliability of Implanted Electromagnetic Transponders in the Prostate: A Multi-Center Analysis

Presented by A. Mahadevan, MD, Cleveland Clinic, Cleveland, OH

Poster Viewing * Genitourinary Cancer # 2213

Stability of Intraprostatic Electromagnetic Transponders in Patients Receiving Radiation Therapy, With and Without Neoadjuvant and/or Concurrent Androgen Suppression Therapy

Presented by G. Weinstein, MD, Sharp Memorial Hospital, San Diego, CA

Poster Viewing * Genitourinary Cancer # 2266

A Comparison of Animal Health Impacts and Implant Stability Between Bronchoscopic Implanted Gold Fiducials and Electromagnetic Transponders in Canine Lung Tissue

Presented by Parag Parikh, MD; Washington University School of Medicine, Saint Louis, MO

Poster Viewing * Lung # 2495

Efficiency of a Non-Ionizing Target Localization System for Radiation Therapy

Presented by D. Beyer, MD, Arizona Oncology Services, Scottsdale, AZ

Poster Viewing * Genitourinary Cancer # 2290

Clinical Impact of a 3 mm versus 5 mm Action Threshold for Correction of Intrafractional Prostate Motion Identified with Electromagnetic Tracking

Presented by Charles Enke, MD., Nebraska Medical Center,

Poster Viewing * Genitourinary Cancer #2275

Prostate Rotation Measured by Electromagnetic Tracking System: A Multi- Center Analysis

Presented by T. Djemil, PhD, Cleveland Clinic, Cleveland, OH
Poster Viewing * Genitourinary Cancer # 2236

About CalypsoŽ Medical Technologies, Inc.

Calypso Medical Technologies, Inc. ("Calypso") is a Seattle, WA based privately held medical device company. Calypso addresses two major issues in modern radiation oncology: errors in treatment set-up and tumor motion during treatment. The Company's proprietary system utilizes miniaturized implanted devices (BeaconŽ electromagnetic transponders) to accurately, objectively and continuously pinpoint the location of tumors in real-time. In addition, the CalypsoŽ 4D Localization System's non-ionizing electromagnetic guidance has the potential to improve work flow efficiency and treatment room utilization. The product is FDA 510(k) cleared for use in the prostate application only. http://www.calypsomedical.com.


Source: Calypso Medical Technologies

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.